Taken together, miR-133a targets a variety of pro-hypertrophic genes, namely SRF, cyclin D2, CTGF, RhoA, NFATc4, angiotensinogen, and AT1R, thus opposing cardiac hypertrophy. Here, AGT is linked to cardiac hypertrophy.